RIGL Q3 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$69M+25.6% YoY

Gross Profit

$65M93.2% margin

Operating Income

$28M40.9% margin

Net Income

$28M40.2% margin

EPS (Diluted)

$1.46

QoQ Revenue Growth

-31.7%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$243M

Total Liabilities

$125M

Stockholders' Equity

$118M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$69M	$55M	+25.6%
Gross Profit	$65M	$47M	+36.9%
Operating Income	$28M	$14M	+102.2%
Net Income	$28M	$12M	+124.6%

Revenue Segments

Gross product sales

$86M63%

Product sales, net

$64M47%

Contract revenues from collaborations

$5M4%

Milestone

$3M2%

Discounts and allowances

-$22M-16%